Regeneron Pharmaceuticals
REGN
$793.74
+1.57%
Regeneron Pharmaceuticals is a fully integrated biotechnology company that discovers, develops, and commercializes medicines across eye disease, cardiovascular disease, cancer, inflammation, and immunology, with a marketed portfolio led by Eylea/Eylea HD (partnered with Bayer), Dupixent (partnered with Sanofi), Libtayo, Praluent, Kevzara, and Lynozyfic for multiple myeloma. The company is one of the largest and most profitable pure-play biotechs in the world, distinguished by its proprietary VelocImmune and VelociSuite antibody discovery platforms, which have generated a deep and repeatable pipeline rather than a single-product franchise. The current investor narrative is dominated by two opposing forces: enthusiasm over the rapid adoption of Eylea HD and Dupixent's expanding label, which drove Q1 2026 revenue growth of 19.0% year over year, versus a significant setback in May 2026 when a Phase 3 trial failure for a key oncology combination sent shares sharply lower and raised questions about pipeline diversification. With 27 analysts covering the name and a consensus buy rating, the debate centers on whether Regeneron's platform can deliver the next leg of growth as Eylea faces biosimilar erosion and oncology disappointments weigh on sentiment.…
REGN
Regeneron Pharmaceuticals
$793.74
Related headlines
Investment Opinion: Should I buy REGN Today?
Regeneron earns a synthesized rating of Buy, anchored by a consensus analyst recommendation of Buy (mean 1.89) and an average target price of $849.32, implying 8.7% upside. The core thesis is that Regeneron's industry-leading profitability, fortress balance sheet, and deeply discounted forward valuation (12.89x PE) provide a margin of safety, while its pipeline offers optionality for multiple expansion as Eylea HD and Dupixent drive growth. The recent pullback from the 52-week high has created an attractive entry point for long-term investors willing to tolerate pipeline binary risk.
The supporting evidence is compelling: revenue grew 19.04% year over year in Q1 2026 to $3.605 billion, with a net margin of 20.17% and gross margin of 81.43%. Free cash flow is robust at $4.155 billion on a trailing basis, and the balance sheet is pristine with debt-to-equity of 0.0866 and a current ratio of 4.13. The forward PE of 12.89x is well below the broader biotech sector average, and the price-to-sales ratio of 5.63x is moderate for a company with 31.41% trailing net margins. Analyst estimates project EPS of $80.03, which would represent significant growth from current levels.
The biggest risks that could invalidate the thesis include further pipeline failures, accelerated Eylea biosimilar erosion, and sustained margin compression. The rating would upgrade to a Strong Buy if the forward PE compresses below 12x or if pipeline readouts succeed, and it would downgrade to Hold if revenue growth decelerates below 15% or if net margins fall below 18%. Relative to its own history, Regeneron is undervalued: the PE has compressed from 36.17x in Q1 2024 to 17.92x today, and the PS ratio has fallen from 33.22x to 5.63x. This suggests the market is pricing in significant pessimism, offering a favorable risk/reward for patient investors.
Sign up to view all
REGN 12-Month Price Forecast
Regeneron presents a balanced risk/reward profile: the stock is attractively valued on forward earnings (12.89x PE) with a fortress balance sheet and strong revenue growth, but margin compression and pipeline setbacks create near-term uncertainty. The analyst consensus is moderately bullish with an average target of $849, yet the wide target range ($730-$1,030) reflects significant disagreement about the pipeline's potential. The low beta (0.193) makes it a defensive holding, but idiosyncratic volatility remains high. I would upgrade to bullish if the company demonstrates margin stabilization and positive pipeline data, and downgrade to bearish if Eylea erosion accelerates or another major trial fails.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Regeneron Pharmaceuticals's 12-month outlook, with a consensus price target around $849.32 and implied upside of +7.0% versus the current price.
Average Target
$849.32
0 analysts
Implied Upside
+7.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$730 - $1030
Analyst target range
Regeneron is covered by 27 analysts, and the consensus recommendation is a buy with a recommendation mean of 1.89 (where 1.0 is a strong buy and 5.0 is a sell). The average price target is $849.32, which against the current price of $781.49 implies approximately 8.7% upside. The consensus leans moderately bullish, but the modest upside to the average target — combined with the stock's recent run to near its 52-week high — suggests that much of the near-term optimism is already priced in. The distribution of ratings, with several firms at Overweight/Buy (Piper Sandler, Cantor Fitzgerald, HSBC, Truist, Benchmark) and others at Equal Weight/Market Perform (Morgan Stanley, RBC Capital, Leerink), reflects a market that is constructive but not uniformly convinced.
The target range spans from a low of $730.00 to a high of $1,030.00, a spread of $300, or roughly 41% of the low target — a wide range that signals meaningful disagreement about the company's trajectory. The high target of $1,030 implies roughly 31.8% upside and likely assumes successful pipeline readouts, accelerating Dupixent and Eylea HD adoption, and multiple expansion back toward historical norms. The low target of $730 sits about 6.6% below the current price and appears to price in continued Eylea biosimilar erosion, further oncology disappointments, and margin compression. Recent institutional activity shows a mix of reaffirmations and at least one upgrade (Benchmark moved from Hold to Buy on July 7, 2026) alongside a downgrade (Leerink moved from Outperform to Market Perform on May 18, 2026, following the Phase 3 failure), indicating that sentiment is in flux. The wide target spread, combined with the stock's low beta of 0.193 but high idiosyncratic volatility, argues for position sizing that accounts for pipeline binary risk rather than treating Regeneron as a low-volatility defensive holding.
Drowning in data?
Find the real signal!
Bulls vs Bears: REGN Investment Factors
The bull case for Regeneron rests on its attractive forward valuation (12.89x PE), robust 19% revenue growth, fortress balance sheet, and strong analyst support, while the bear case centers on margin compression, pipeline setbacks, and biosimilar threats. Currently, the bull evidence appears stronger given the stock's 37.54% one-year outperformance and low beta, but the margin deterioration and May oncology failure are significant concerns. The single most important tension is whether Regeneron's pipeline can deliver new growth drivers to offset Eylea erosion and justify multiple expansion; resolution of this debate will determine whether the stock re-rates higher or remains range-bound. The wide analyst target range ($730 to $1,030) underscores the uncertainty, with the market clearly awaiting clearer pipeline visibility.
Bullish
- Revenue growth accelerating at 19% YoY: Q1 2026 revenue of $3.605 billion grew 19.04% year over year, driven by Eylea HD adoption and Dupixent label expansion. This growth rate is robust for a company of Regeneron's scale and demonstrates the resilience of its core franchises despite biosimilar headwinds.
- Deeply undervalued on forward earnings: The stock trades at a forward PE of 12.89x and a trailing PE of 17.92x, with a forward earnings yield of roughly 10.2% based on consensus EPS of $80.03. This valuation is near historical lows and well below the premium multiples typically commanded by large-cap biotech peers.
- Fortress balance sheet with negligible debt: Debt-to-equity is just 0.0866, the current ratio is 4.13, and trailing free cash flow is $4.155 billion. This financial strength allows Regeneron to fund its pipeline internally and pursue bolt-on M&A without dilution or balance sheet strain.
- Strong analyst consensus and upside: 27 analysts rate the stock a buy with a recommendation mean of 1.89, and the average price target of $849.32 implies 8.7% upside. The high target of $1,030 suggests 31.8% upside if pipeline readouts succeed and multiples expand.
Bearish
- Margin compression from rising R&D: Net margin fell to 20.17% in Q1 2026 from 38.89% in Q3 2025, and gross margin declined 468 basis points to 81.43%. R&D spending jumped 22.8% year over year to $1.645 billion, pressuring near-term earnings.
- Pipeline setback raises diversification concerns: The May 2026 Phase 3 failure for a key oncology combination sent shares sharply lower and highlighted the binary risk inherent in Regeneron's pipeline. This event triggered a downgrade from Leerink and raised questions about the company's ability to deliver new blockbusters.
- Eylea biosimilar erosion threat: Eylea, a core franchise, faces increasing biosimilar competition that could erode revenue. The sequential revenue decline from $3.884 billion in Q4 2025 to $3.605 billion in Q1 2026 partly reflects this pressure, and the trend may accelerate.
- High PEG ratio signals growth premium: The PEG ratio of 3.38 indicates that investors are paying a premium for growth that may not be sustainable. With revenue growth at 19%, the multiple is not justified on a PEG basis, suggesting valuation risk if growth decelerates.
REGN Technical Analysis
Regeneron is in a sustained, powerful uptrend, with the stock up 37.54% over the past year versus a 16.22% gain for the S&P 500, delivering 21.32 percentage points of relative strength. At the current price of $781.49, the shares sit at roughly 90.6% of the 52-week range (low of $541.00, high of $859.34), positioning them near the upper end of their annual band — a sign of strong momentum but also of limited near-term margin for error. The stock has recovered decisively from its May 2026 trough near $600, when the Phase 3 oncology failure triggered a sharp selloff, and the rebound to within about 9% of the 52-week high confirms that buyers have reasserted control of the trend. Momentum has cooled at the margin: the 1-month change of -2.07% lags the 3-month gain of 27.67% and the 1-year gain of 37.54%, indicating a deceleration or consolidation phase after a strong summer rally. Notably, the 1-month relative strength of -1.01% versus the S&P 500's -1.06% shows Regeneron tracking the market almost exactly over the past month, while the 3-month relative strength of +24.63% underscores how dramatically it outperformed during the spring-to-summer advance. The 6-month change of just 4.79% and YTD change of 0.67% reveal that the stock spent much of the first half of 2026 recovering from the May drawdown, with the bulk of gains concentrated in the July–September window. Key technical support sits at the 52-week low of $541.00, with a more immediate support zone around the $600 area that marked the May capitulation low; resistance is defined by the 52-week high of $859.34, and a breakout above that level would signal a fresh leg higher and likely draw momentum buyers. A breakdown below $600 would invalidate the recovery thesis and reopen the door to the $541 low. The stock's beta of 0.193 is remarkably low — roughly 81% less volatile than the market — which means Regeneron has historically been a defensive holding, though its recent 27.67% three-month surge and -26.05% maximum drawdown show that idiosyncratic, pipeline-driven volatility can overwhelm its low market beta.
Beta
0.19
0.19x market volatility
Max Drawdown
-26.1%
Largest decline past year
52-Week Range
$541-$859
Price range past year
Annual Return
+41.7%
Cumulative gain past year
| Period | REGN Return | S&P 500 |
|---|---|---|
| 1m | -1.2% | -2.0% |
| 3m | +29.1% | +1.4% |
| 6m | +6.7% | +15.0% |
| 1y | +41.7% | +15.7% |
| ytd | +2.2% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
REGN Fundamental Analysis
Regeneron's revenue trajectory remains solidly positive, with Q1 2026 revenue of $3.605 billion representing 19.04% year-over-year growth over Q1 2025's $3.029 billion. The multi-quarter trend shows healthy but uneven progression: revenue rose from $3.675 billion in Q2 2025 to $3.754 billion in Q3 2025, dipped to $3.884 billion in Q4 2025, and then moderated to $3.605 billion in Q1 2026, a sequential decline that partly reflects seasonality and the loss of a one-time boost from Q3 2025's unusually high other income. Segment data shows collaboration revenue of $1.900 billion and product revenue of $1.535 billion in the most recent period, with collaboration revenue (largely Sanofi-partnered Dupixent profits) now the single largest contributor — a concentration risk if partnership economics shift. The 19% growth rate is respectable for a company of this scale but represents a deceleration from the mid-2020s pace, and the investment case increasingly hinges on Eylea HD conversion and Dupixent label expansion rather than new blockbuster launches.
Profitability remains a core strength: Q1 2026 net income was $727.2 million on a net margin of 20.17%, with a gross margin of 81.43% and an operating margin of 17.83%. However, margins have compressed meaningfully from the 2025 peaks — Q3 2025 posted a 38.89% net margin and Q2 2025 a 37.86% net margin, both far above the current 20.17% — driven by a sharp step-up in R&D spending (from $1.338 billion in Q1 2025 to $1.645 billion in Q1 2026, a 22.8% increase) and the absence of the large one-time other-income gains that flattered mid-2025 results. Gross margin has also drifted from 86.11% in Q3 2025 to 81.43% in Q1 2026, a 468-basis-point decline that likely reflects product mix and Eylea pricing pressure. The company remains highly profitable in absolute terms, but the direction of travel on margins is negative, and the market will watch whether R&D intensity translates into pipeline wins or continues to dilute near-term earnings.
The balance sheet is exceptionally strong: debt-to-equity is just 0.0866, the current ratio is 4.13, and free cash flow on a trailing basis is $4.155 billion, giving Regeneron enormous financial flexibility. Q1 2026 operating cash flow was $1.079 billion against capital expenditures of $230.6 million, yielding free cash flow of $848.3 million, while the company returned capital via $794.3 million of stock repurchases and $97.8 million of dividends. ROE of 14.41% and ROA of 6.53% are solid though below the company's historical peaks, reflecting the margin compression noted above. With cash of $2.971 billion and negligible leverage, Regeneron funds its pipeline internally and has ample capacity for bolt-on M&A — a critical advantage given the oncology setback and the need to replenish the pipeline.
Quarterly Revenue
$3.6B
2026-03
Revenue YoY Growth
+19.0%
YoY Comparison
Gross Margin
81.4%
Latest Quarter
Free Cash Flow
$4.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is REGN Overvalued?
Because Regeneron is solidly profitable — Q1 2026 net income of $727.2 million and trailing net margin of 31.41% — the PE ratio is the appropriate primary valuation metric. The stock trades at a trailing PE of 17.92x and a forward PE of 12.89x, an unusually wide gap that implies the market expects meaningful earnings growth over the next twelve months. That expectation is supported by consensus estimated EPS of $80.03, which against the current price of $781.49 implies a forward earnings yield of roughly 10.2% — a level that would be attractive for a large-cap biotech if the estimates prove durable. The forward PE of 12.89x is notably low in absolute terms, suggesting either that the market is discounting pipeline risk (the May oncology failure) or that the stock is genuinely undervalued relative to its earnings power.
Relative to the broader biotechnology sector, Regeneron screens as a value proposition: its trailing PE of 17.92x and forward PE of 12.89x compare favorably to the premium multiples typically commanded by large-cap biotech peers, and its price-to-sales ratio of 5.63x and EV/EBITDA of 13.81x are moderate for a company with 31.41% net margins and 85.35% gross margins. The PEG ratio of 3.38, however, signals that the stock is not cheap relative to its growth rate — investors are paying up for growth that, at 19% revenue expansion, does not fully justify the multiple on a PEG basis. The price-to-book ratio of 2.58x is low for a biotech with Regeneron's returns, reflecting the company's substantial retained earnings and asset base. On balance, the valuation reflects a market that respects Regeneron's profitability and balance sheet but is unwilling to pay a premium multiple until pipeline execution improves.
Historically, Regeneron's valuation has compressed dramatically: the PE ratio stood at 36.17x in Q1 2024 and 27.63x in Q1 2026, while the PS ratio has fallen from 33.22x in Q1 2024 to 22.29x in Q1 2026 and the current 5.63x on a trailing basis. The stock's price-to-book has declined from 3.87x in Q1 2024 to 2.58x today, placing it near the bottom of its multi-year band. This compression reflects both earnings growth outpacing price appreciation and the market's de-rating of the stock following pipeline setbacks. At current levels, the valuation is near historical lows on most metrics, which could represent a genuine value opportunity if the pipeline stabilizes — or a value trap if Eylea erosion and oncology failures continue to weigh on growth.
PE
17.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 5x~28x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks for Regeneron are moderate but rising. The company's net margin has compressed sharply from 38.89% in Q3 2025 to 20.17% in Q1 2026, driven by a 22.8% year-over-year increase in R&D spending to $1.645 billion and a 468-basis-point decline in gross margin to 81.43%. While the balance sheet is exceptionally strong with debt-to-equity of 0.0866 and $4.155 billion in trailing free cash flow, the earnings volatility is a concern: quarterly EPS has ranged from $6.99 to $14.09 over the past year, and the company's reliance on collaboration revenue ($1.900 billion in Q1 2026) introduces concentration risk if partnership terms change. Additionally, the sequential revenue decline from $3.884 billion in Q4 2025 to $3.605 billion in Q1 2026 highlights potential seasonality and the impact of biosimilar erosion on Eylea.
Market and competitive risks are significant given Regeneron's premium valuation relative to its growth rate and the binary nature of biotech pipelines. The stock trades at a PEG ratio of 3.38, suggesting that investors are paying up for growth that may not materialize if pipeline setbacks continue. The May 2026 Phase 3 oncology failure triggered a sharp selloff and a downgrade from Leerink, underscoring the stock's sensitivity to clinical news. With a beta of 0.193, Regeneron is less correlated to market swings, but its idiosyncratic volatility is high, as evidenced by a maximum drawdown of -26.05% over the past year. Competitive threats include Eylea biosimilars and rival immunology drugs, while regulatory and pricing pressures in the U.S. healthcare sector could further weigh on sentiment.
The worst-case scenario for Regeneron would involve a combination of accelerating Eylea biosimilar erosion, another major pipeline failure, and sustained margin compression. In this scenario, the stock could retest its 52-week low of $541.00, representing a 30.8% decline from the current price of $781.49. The analyst low target of $730 implies a more moderate 6.6% downside, but a breakdown below the $600 support level (the May capitulation low) could open the door to the $541 low. Investors could lose approximately 31% from current levels in this adverse scenario, which is plausible given the stock's historical max drawdown of 26.05% and the binary risks inherent in biotechnology.
FAQ
The key risks include: 1) Pipeline binary risk, as evidenced by the May 2026 Phase 3 oncology failure that caused a sharp selloff and a downgrade; 2) Eylea biosimilar erosion, with sequential revenue declining from $3.884 billion in Q4 2025 to $3.605 billion in Q1 2026; 3) Margin compression, with net margin falling from 38.89% to 20.17% due to a 22.8% increase in R&D spending; and 4) Concentration in collaboration revenue, which at $1.900 billion now exceeds product revenue. These risks are ranked from highest to lowest severity, with pipeline failures being the most immediate threat to the investment thesis.
The 12-month forecast includes a base case (55% probability) with a target range of $800-$900, assuming revenue growth of 15-18% and stable margins; a bull case (25% probability) targeting $900-$1,030 if pipeline readouts succeed and multiples expand; and a bear case (20% probability) targeting $541-$730 if Eylea erosion accelerates and another trial fails. The most likely scenario is the base case, hinging on Regeneron maintaining mid-teens revenue growth and avoiding major pipeline setbacks. The wide range reflects the binary nature of biotech catalysts.
Regeneron appears undervalued on forward earnings, trading at a forward PE of 12.89x and a trailing PE of 17.92x, both near multi-year lows. The price-to-sales ratio of 5.63x and EV/EBITDA of 13.81x are moderate for a company with 31.41% net margins and 85.35% gross margins. However, the PEG ratio of 3.38 indicates that the stock is not cheap relative to its growth rate, suggesting the market is pricing in pipeline risk. Compared to its own history, the PE has compressed from 36.17x in Q1 2024, implying the market expects slower growth or further setbacks.
Regeneron is a good buy for long-term investors with a tolerance for pipeline binary risk, given its forward PE of 12.89x, 19% revenue growth, and fortress balance sheet. The analyst consensus target of $849 implies 8.7% upside, and the high target of $1,030 suggests 31.8% upside if pipeline readouts succeed. However, the biggest downside risk is a retest of the 52-week low of $541, representing a 30.8% decline, if Eylea erosion accelerates or another trial fails. Therefore, it is most suitable for patient investors who can withstand volatility and hold for at least 2-3 years to realize the pipeline's value.
Regeneron is best suited for long-term investment (minimum 2-3 years) due to its low beta of 0.193, strong free cash flow of $4.155 billion, and pipeline optionality that requires time to materialize. Short-term trading is risky given the stock's idiosyncratic volatility (max drawdown of -26.05%) and binary clinical events. The company pays a modest dividend (yield 0.46%), so income is not a primary driver. Investors should focus on the pipeline's progression and margin trends rather than quarterly fluctuations.
